Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
An FDA-approved GLP-1 receptor agonist for type 2 diabetes (Victoza) and chronic weight management (Saxenda), the first GLP-1 agonist approved for obesity treatment.
Verified purity per dollar — the cheapest that's actually been tested
No vendor for Liraglutide currently meets our listing bar — every source we track is below a C trust grade, or doesn't have enough verified COA data yet. We'd rather show nothing than point you at one we can't stand behind.
Single-vial list prices by default for a fair head-to-head — switch to Multi-vial / bulk for pack pricing. Estimates only; verify at vendor before purchase. For research use only. Not medical advice.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Use the Full safety panel filter to require endotoxin, sterility, and heavy-metals testing on the current batch — not just HPLC purity.
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015; PMID 26132939) demonstrated ~8% body-weight loss at 3.0 mg daily over 56 weeks, and the SCALE Diabetes trial (Davies et al., JAMA 2015; PMID 26284720) showed 6.0% weight loss in adults with type 2 diabetes. The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016; PMID 27295427) demonstrated a 13% relative reduction in major adverse cardiovascular events in type 2 diabetes with established CVD or high CV risk. A pediatric Phase 3 trial (Kelly et al., NEJM 2020; PMID 32233338) supported Saxenda's FDA approval for adolescents ≥12 years with obesity. While less effective than newer GLP-1 agonists for weight loss, liraglutide has the longest track record and most extensive real-world safety data. The daily dosing requirement is its main disadvantage versus weekly semaglutide.
This platform provides informational tools only, not medical advice.
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes; Pi-Sunyer et al., NEJM 2015)
2015
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial (Davies et al., JAMA 2015)
2015
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER; Marso et al., NEJM 2016)
Prices verified as of July 2026. Actual prices may vary. For research use only.
2016
Disclosed Labs